RECAF market screening detects the CA-62 antigen (specific to cancer cells) that provides 90-95% accuracy rate when detecting evidence of cancer in a patient.
Sessions begins on Jun 3, 2023 at 8:00AM
Hall A1 12000
Over 20 million prostate-specific antigen (PSA) tests are conducted each year in North America, many as part of standard underwriting practice to approve insurance applicants for coverage.
600,000 of all PSA tests indicate a false positive for prostate cancer, or 75% of all elevated PSA cases. This leads to delays, declines, and ratings for insurance applicants who would otherwise have qualified with no restrictions for coverage.
The CA-62 indicator is a revolutionary new cancer testing parameter that offers:
Biopsies remain one of the most commonly issued procedures for confirming cancer. But a biopsy can be invasive, costly*, and risk infection. Additionally, 1 in 5 biopsies have been found to return a false positive.
*$15,000 average,
Determine results accurately and adjust your clients to insurable cases. Up to 480,000 cases across North America may be insurable with an accurate RECAF result.
Higher precision over standard tests and invasive procedures. The CA-62 marker has been tested in over 5000 cases across North America, Europe, and Asia.
CA-62 Testing for Insurers and Reinsurers
The insurance industry is due for a change in how it conducts diagnostics, biopsies, and blood tests. Insurers and reinsurers are looking for faster, more reliable tools to qualify their clients. CA-62 testing presents bold new opportunities for businesses who need reliable and accurate testing results.
wellness
first
Consumers are engaged with their own health, and less-invasive testing parameters mean they are more receptive to proactive screening for cancer.
innovative
tech
Reduce cost and work-load in labs and reduce false positives with a reliable and effective screening tool.
wider testing
reach
As a simpler and less-invasive testing parameter, CA-62 is a strong fit for group benefit plans and executive wellness assessment.
The team at UCM Technologies consists of medical, insurance and financial professionals with years of experience in their respective fields. Our founding partners are pioneers in the insurance space online marketing, product development, underwriting and life insurance. Our founding partners are pioneers in online marketing, product development, underwriting and life insurance.
Get Updates on UCM and CA-62 Developments
UCM diagnostic technology for CA-62 markers will soon be available to insurers and underwriters. A CA-62 marker allows underwriting to get more accurate results when determining the presence of cancer.
To get more information on UCM Technology diagnostic tools, please fill out a contact form.